Biosimilar Pathway Would Disappear If ACA Repealed, Gottlieb Says

Asked during Senate hearing whether the 351(k) pathway would be repealed along with the rest of the ACA under a pending lawsuit, the outgoing commissioner acknowledged that it would,  but said he hoped Congress would create it again.